Ten new products added to DND list


Share post:

The regulators have added 10 new products to the ‘Drugs for which Discount is Not Deducted’ (DND) list from Thursday (01 June).

Community Pharmacy England on behalf of its members had made further applications to the Department of Health and Social Care (DHSC) and the NHS Business Services Authority (NHSBSA), resulting in the inclusion of 10 new products in the DND.

More than 610 products are granted DND status following checks made by Community Pharmacy England’s dispensing & supply team over the past 3 years to ensure fair reimbursement for our members.

The DND list is updated monthly by the DHSC and includes grouped and individual items. Individual items are separately listed in Part II of the Drug Tariff. Any items covered by the ‘Group Items’ heading are not listed again individually in Part II.

“We will continue our work to assess whether other drugs and appliances fulfil the current DND entry requirements under either the ‘Group’ and ‘Individual item’ criteria and make applications to NHSBSA and DHSC, on behalf of our members accordingly,” said Community Pharmacy England.

Ten products added to DND list on 1 June 2023:

  • Ampicillin 250mg capsules
  • Chlortalidone 50mg tablets
  • Diazoxide 50mg tablets
  • Eudemine 50mg tablets
  • Flutamide 250mg tablets
  • Hydrocortisone 10mg soluble tablets sugar free
  • Hydrocortisone 2.5mg tablets
  • Mianserin 30mg tablets
  • Pyrazinamide 500mg tablets
  • Sitagliptin 100mg/5ml oral solution sugar


Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...

Grundon launches maiden UK-wide inhaler recycling programme

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and...

‘Record fine imposed on hydrocortisone manufacturers for dominant position abuse and 10,000% price increase’

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority’s (CMA) findings against two pharmaceutical manufacturers...

Vision Report: Legal reforms, adequate funding imperative for success of community pharmacy

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document...